Sarepta Therapeutics | SRPT - Ebitda

Stock Price
17.55
Daily Change
-1.13 -6.05%
Monthly
-17.10%
Yearly
-51.83%
Q2 Forecast
17.20

Sarepta Therapeutics reported $-252.2M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
Incyte USD 367.97M 46.53M Mar/2026
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026